TMCnet News
Bovie Medical Corporation Hires J-Plasma Product Development ManagerBovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced that it has hired Mark Charbonneau as J-Plasma® Product Development Manager. Prior to joining Bovie, Mark was an engineering manager for Centrix and senior manufacturing engineer for Ventripoint Diagnostics. Previously, Mark worked in senior engineering roles at companies including Cenorin, Archus Orthopedics and Salient Surgical Technologies. He brings more than 14 years of experience to Bovie and received a B.S. in engineering from the University of Massachusetts. "This hire is part of our broader strategy to expand a highly-credentialed team to accelerate the adoption of J-Plasma," said Robert L. Gershon, Chief Executive Officer. "Mark comes to Bovie Medical with a proven track record in new medical device roll-outs, product design and a strong technical background." Mr. Charbonneau's hire was effective May 18, 2015. He reports to Mr. Shawn Roman, Director of Research and Development. The terms of Mark's employment with Bovie include an inducement grant of 10,000 options with a 4 year vesting period. The strike price of the inducement grant will equal the closing price as of today, May 26, 2015. The options shall vest and be exercisable in four equal annual installments beginning on the first anniversary of the effective date. About Bovie Medical Corporation Bovie Medical Corporation is a leading maker of medical devces and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company's own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie Medical Corporation's website www.boviemed.com. Cautionary Statement on Forward-Looking Statements Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Report on Forms 10-Q for the quarter ended March 31, 2015 and 10-K for the year ended December 31, 2014. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150526006226/en/ |
